Abbott Laboratories (ABT) Stock Analysis and Metrics

Abbott Laboratories

NYSE: ABT

$103.06 ▲ +2.31 (+2.29%)

At close: Jul 24, 2026 · 4:04 PM UTC

Financial Ratios

Market Cap201.40 Bn

P/E27.98

P/S4.46

Div. Yield0.02

ROIC (Qtr)0.01

Total Debt (Qtr)34.05 Bn

Revenue Growth (1y) (Qtr)7.78

Add ratio to table…

About

Abbott Laboratories discovers, develops, manufactures, and sells a broad line of healthcare products worldwide. The company states its mission is to help people live their healthiest possible lives. Abbott operates in more than 160 countries employing about 115,000 staff with roughly 69% based outside the United States.

Revenue comes from sales of pharmaceutical diagnostic nutrition and medical device products. Products are distributed through wholesalers distributors government agencies hospitals clinics pharmacies retailers physicians offices consumers and alternate care testing sites globally. Ongoing innovation and a global supply chain support revenue across emerging and developed markets.

The company reports financial performance through four operating segments defined by product lines. These segments are Established Pharmaceutical Products Diagnostic Products Nutritional Products and Medical Devices.

• Established Pharmaceutical Products: This segment markets branded generic pharmaceuticals primarily outside the United States with a focus on emerging markets. Its portfolio features gastroenterology agents such as Creon cardiovascular drugs like Lipanthyl and Synthroid respiratory agents such as clarithromycin and Influvac and biologic biosimilars in oncology immunology and women s health distributed via wholesalers distributors government agencies healthcare facilities pharmacies and independent retailers.

• Diagnostic Products: This segment provides diagnostic systems and tests used in laboratories and point of care settings worldwide. Offerings include core lab systems molecular diagnostics for HIV hepatitis and SARS CoV 2 point of care devices like i STAT rapid tests such as BinaxNOW and informatics tools for hospital and laboratory customers.

• Nutritional Products: This segment offers pediatric and adult nutritional products including infant formula adult nutrition and enteral feeding solutions. Brands feature Similac and Ensure lines with products such as Glucerna and Pedialyte sold to consumers institutions wholesalers retailers healthcare facilities government agencies and third party distributors.

• Medical Devices: This segment develops and sells devices for rhythm management electrophysiology heart failure vascular structural heart diabetes care and neuromodulation. Products include pacemakers defibrillators stents ventricular assist devices glucose monitors and neuromodulation stimulators sold worldwide through wholesalers hospitals ambulatory surgery centers physicians offices consumers and distributors.

Abbott Laboratories holds a diversified position in the global healthcare industry competing with other major healthcare and pharmaceutical companies. The company leverages its broad product portfolio global distribution network and ongoing investment in research and development to maintain competitive advantages. Its scale supports innovation and responsiveness to regulatory changes while strong brand recognition aids customer loyalty.

The company sells its products to wholesalers distributors government agencies hospitals clinics pharmacies retailers physicians offices consumers and alternate care testing sites worldwide. Customers span pharmaceutical distributors and government agencies diagnostic hospitals labs and public health agencies nutrition retail consumers institutions and government programs and medical device users hospitals ambulatory centers physicians and patients.

Investment Thesis

▲ Bull case

Abbott Laboratories is positioned to capitalize on significant long-term growth opportunities in cancer diagnostics through its Exact Sciences acquisition, which adds a high-growth platform beyond Cologuard into multi-cancer early detection (MCED), molecular residual disease (MRD), and therapy selection. The company’s Cancerguard MCED test and Oncodetect MRD test were highlighted in ASCO 2026 presentations, demonstrating strong clinical utility across the cancer care continuum without adding patient burden. Management emphasized that Exact Sciences is growing faster than the overall guidance range, with Cologuard alone driving mid-teens growth and international markets showing high-teens expansion. The integration is progressing well, with Jake Orville leading the business and direct reporting to the CEO, ensuring strategic focus. Abbott’s global distribution, regulatory expertise, and established relationships with healthcare systems provide a scalable foundation to expand Cologuard and its complementary tests internationally, particularly as screening guidelines evolve. The ACS reaffirmation of Cologuard and Cologuard Plus as preferred screening options for adults 45+ removes a key barrier to adoption and supports reimbursement alignment, while the company’s development of a blood-based test via its Freenome partnership addresses non-adherers to stool-based screening. With approximately 50 million Americans not up to date on CRC screening and declining colonoscopist supply creating a capacity bottleneck, Cologuard’s 95% sensitivity and home-based convenience position it to capture growing demand. The company’s care gap programs and patient navigation infrastructure further drive adherence and rescreening, with 25% of tests already being rescreens and rescreen rates increasing over time. Internationally, Abbott’s engagement with health ministers in Asia and Europe confirms strong demand for cancer screening solutions, and its ability to adapt offerings to local markets enhances penetration. This business is not merely an add-on but a trajectory-changing platform that could significantly uplift long-term growth beyond the current 6.5% to 7.5% comparable sales guidance, especially as MCED and MRD tests gain traction in precision oncology pathways.

Abbott Laboratories is positioned to capitalize on significant long-term growth opportunities in cancer diagnostics through its Exact Sciences acquisition, which adds a high-growth platform beyond Cologuard into multi-cancer early detection (MCED), molecular residual disease (MRD), and therapy selection. The company’s Cancerguard MCED test and Oncodetect MRD test were highlighted in ASCO 2026 presentations, demonstrating strong clinical utility across the cancer care continuum without adding patient burden. Management emphasized that Exact Sciences is growing faster than the overall guidance range, with Cologuard alone driving mid-teens growth and international markets showing high-teens expansion. The integration is progressing well, with Jake Orville leading the business and direct reporting to the CEO, ensuring strategic focus. Abbott’s global distribution, regulatory expertise, and established relationships with healthcare systems provide a scalable foundation to expand Cologuard and its complementary tests internationally, particularly as screening guidelines evolve. The ACS reaffirmation of Cologuard and Cologuard Plus as preferred screening options for adults 45+ removes a key barrier to adoption and supports reimbursement alignment, while the company’s development of a blood-based test via its Freenome partnership addresses non-adherers to stool-based screening. With approximately 50 million Americans not up to date on CRC screening and declining colonoscopist supply creating a capacity bottleneck, Cologuard’s 95% sensitivity and home-based convenience position it to capture growing demand. The company’s care gap programs and patient navigation infrastructure further drive adherence and rescreening, with 25% of tests already being rescreens and rescreen rates increasing over time. Internationally, Abbott’s engagement with health ministers in Asia and Europe confirms strong demand for cancer screening solutions, and its ability to adapt offerings to local markets enhances penetration. This business is not merely an add-on but a trajectory-changing platform that could significantly uplift long-term growth beyond the current 6.5% to 7.5% comparable sales guidance, especially as MCED and MRD tests gain traction in precision oncology pathways.

▼ Bear case

Abbott Laboratories’ Nutrition business faces persistent structural challenges that are being underestimated by management’s optimistic volume recovery narrative, with comparable sales declining 7.7% in Q1 and Adult Nutrition down 5.9% despite pricing actions intended to stimulate volume. The company attributes the decline to lapping prior-year shelf restocking and claims volume is beginning to follow pricing reductions, yet there is no clear evidence of sustainable volume growth acceleration—only early, anecdotal signals in U.S. Ensure sales that may reflect temporary promotional elasticity rather than fundamental demand recovery. Management’s reliance on new product launches and portfolio diversification as growth drivers overlooks the reality that the U.S. Adult Nutrition market is mature and facing intense competition from private-label brands and emerging functional nutrition players, particularly in the Ensure and Pediatric segments where Abbott has historically led. The strategic pricing actions implemented in Q4 2025 may be eroding margin without delivering proportional volume gains, especially if consumers are shifting to lower-cost alternatives or if the products are perceived as commoditized. Furthermore, the business model’s dependence on institutional channels (hospitals, long-term care) and retail makes it vulnerable to shifting reimbursement policies and consumer preferences toward whole-food or plant-based nutrition alternatives. Abbott’s claim that it is “not making long-term strategic decisions based on near-term challenges” risks ignoring a secular decline in traditional branded nutritionals, where growth has been stagnant for years and innovation cycles are failing to generate meaningful differentiation. Without a clear path to restoring mid-single-digit comparable growth in Nutrition—a segment that once contributed meaningfully to overall performance—the company’s ability to meet its 6.5% to 7.5% sales guidance becomes increasingly dependent on other segments, increasing execution risk across the portfolio.

Abbott Laboratories’ Nutrition business faces persistent structural challenges that are being underestimated by management’s optimistic volume recovery narrative, with comparable sales declining 7.7% in Q1 and Adult Nutrition down 5.9% despite pricing actions intended to stimulate volume. The company attributes the decline to lapping prior-year shelf restocking and claims volume is beginning to follow pricing reductions, yet there is no clear evidence of sustainable volume growth acceleration—only early, anecdotal signals in U.S. Ensure sales that may reflect temporary promotional elasticity rather than fundamental demand recovery. Management’s reliance on new product launches and portfolio diversification as growth drivers overlooks the reality that the U.S. Adult Nutrition market is mature and facing intense competition from private-label brands and emerging functional nutrition players, particularly in the Ensure and Pediatric segments where Abbott has historically led. The strategic pricing actions implemented in Q4 2025 may be eroding margin without delivering proportional volume gains, especially if consumers are shifting to lower-cost alternatives or if the products are perceived as commoditized. Furthermore, the business model’s dependence on institutional channels (hospitals, long-term care) and retail makes it vulnerable to shifting reimbursement policies and consumer preferences toward whole-food or plant-based nutrition alternatives. Abbott’s claim that it is “not making long-term strategic decisions based on near-term challenges” risks ignoring a secular decline in traditional branded nutritionals, where growth has been stagnant for years and innovation cycles are failing to generate meaningful differentiation. Without a clear path to restoring mid-single-digit comparable growth in Nutrition—a segment that once contributed meaningfully to overall performance—the company’s ability to meet its 6.5% to 7.5% sales guidance becomes increasingly dependent on other segments, increasing execution risk across the portfolio.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2019)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2019)

Peer Comparison

Create an account

Sign In

Reset Password